Expression of cathepsins S and D signals a distinctive biochemical trait in CD34 + hematopoietic stem cells of relapsing

Abstract

Background:

The elucidation of mechanistic aspects of relapsing–remitting multiple sclerosis (RRMS) pathogenesis may offer valuable insights into diagnostic decisions and medical treatment.

Results:

Two lysosomal proteases, cathepsins S and D (CatS and CatD), display an exclusive pattern of expression in CD34⁺ hematopoietic stem cells (HSCs) from peripheral blood of acute MS (A-MS) patients (n = 20). While both enzymes normally exist as precursor forms in the HSCs of healthy individuals (n = 30), the same cells from A-MS patients consistently exhibit mature enzymes. Further, mature cathepsins are expressed at lower rates in stable MS subjects (S-MS, n = 15) and revert to precursor proteins after interferon-β1a treatment (n = 5). Mature CatD and CatS were induced in HSCs of healthy donors that were either co-cultured with PBMCs of A-MS patients or exposed to their plasma, suggesting a functional involvement of soluble agents. Following HSC exposure to several cytokines known to be implicated in MS, and based on relative cytokine levels displayed in A-MS, S-MS and control individuals, we identified IL-16 as a specific cell signaling factor associated with cathepsin processing.

Conclusions:

These data point to an evident correlation between CatS and CatD expression and MS clinical stage, and define a biochemical trait in HSCs with functional, medical, and diagnostic relevance.

Keywords

multiple sclerosis stem cell cathepsins diagnosis

Get full access to this article

View all access options for this article.

References

Stadelmann

. Multiple sclerosis as a neurodegenerative disease: Pathology, mechanisms and therapeutic implications. Curr Opin Neurol 2011; 24: 224–229.

Frohman

Racke

Raine

. Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med 2006; 354: 942–945.

Kieseier

Stüve

. A critical appraisal of treatment decisions in multiple sclerosis — old versus new. Nat Rev Neurol 2011; 7: 255–262.

Reiser

Adair

Reinheckel

. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 2010; 120: 3421–3431.

Delamarre

Pack

Chang

. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 2005; 307: 1630–1634.

Honey

Rudensky

. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003; 3: 472–482.

Nagai

Murakawa

Terashima

. Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurol 2000; 55: 1828–1832.

Bever

Garver

. Increased cathepsin B activity in multiple sclerosis brain. J Neurol Sci 1995; 131: 71–73.

Haves-Zburof

Paperna

Gour-Lavie

. Cathepsins and their endogenous inhibitors cystatins: Expression and modulation in multiple sclerosis. J Cell Mol Med 2011; 15: 2421–2429.

10.

Staun-Ram

Miller

. Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: Modulation by interferon-β and role played in cell migration. J Neuroimmunol 2011; 232: 200–206.

11.

Clark

Malcangio

. Microglial signalling mechanisms: Cathepsin S and Fractalkine. Exp Neurol 2012; 234: 283–292.

12.

Muraro

Vergelli

Kalbus

. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111–129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire. J Clin Invest 1997; 100: 339–349.

13.

Beck

Schwarz

Schröter

. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol 2001; 31: 3726–3736.

14.

Pritzker

Joshi

Gowan

. Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 2000; 39: 5374–5381.

15.

Tanaka

Yamada

. Induced expression of cathepsins and cystatin C in a murine model of demyelination. Neurochem Res 2007; 32: 311–320.

16.

Baugh

Black

Westwood

. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 2011; 36: 201–209.

17.

Martino

Tiribuzi

Ciraci

. Coordinated involvement of cathepsins S, D and cystatin C in the commitment of hematopoietic stem cells to dendritic cells. Int J Biochem Cell Biol 2011; 43: 775–778.

18.

McDonald

Compston

Edan

. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121.

19.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: Revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.

20.

Kurtzke

. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

21.

Tiribuzi

Martino

Ciraci

. Non-redundant roles of cathepsins L, B and S in CD1a+ dendritic cells knocked-down for cathepsin S by RNA interference. Minerva Biotecnol 2008; 20: 59–67.

22.

Chen

Miao

. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J Neuroimmunol 2012; 243: 56–60.

23.

Kitamura

Kamon

Sawa

. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 2005; 23: 491–502.

24.

Della Bella

Nicola

Timofeeva

. Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells? Blood 2004; 104: 4020–4028.

25.

Vrethem

Kvarnstrom

Stenstam

. Cytokine mapping in cerebrospinal fluid and blood in multiple sclerosis patients without oligoclonal bands. Mult Scler 2012; 18: 669–673.

26.

Nicoletti

Di Marco

Patti

. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha. Cytokine 2000; 12: 682–687.

27.

Skundric

Zhou

Cruikshank

. Increased levels of bioactive IL-16 correlate with disease activity during relapsing experimental autoimmune encephalomyelitis (EAE). J Autoimmun 2005; 25: 206–214.

28.

Skundric

Cai

Cruikshank

. Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J Neuroinflamm 2006; 26: 3–13.

29.

Kürtüncü

Tüzün

Türkoğlu

. Effect of short-term interferon-β treatment on cytokines in multiple sclerosis: Significant modulation of IL-17 and IL-23. Cytokine 2012; 59: 400–402.

30.

Gupta

Singh

Dastidar

. Cysteine cathepsin S as an immunomodulatory target: Present and future trends. Expert Opin Ther Targets 2008; 12: 291–299.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

4.82 MB

11.84 MB

5.31 MB

9.41 MB

0.02 MB

9.27 MB

Expression of cathepsins S and D signals a distinctive biochemical trait in CD34 + hematopoietic stem cells of relapsing–remitting multiple sclerosis patients